Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer

Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies.

(2017) R. R. Furman et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways

(2016) BO ZHOU et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML

(2016) O Lindblad et al.   ONCOGENE

Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms

(2015) Christopher Stamatkin et al.   CANCER BIOLOGY & THERAPY

A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

(2015) Johanna C. Bendell et al.   INVESTIGATIONAL NEW DRUGS

PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers

(2015) Q Wang et al.   ONCOGENE

Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer

(2014) Sara Tolaney et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

(2014) K. P. Papadopoulos et al.   CLINICAL CANCER RESEARCH

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

(2014) P. L. Bedard et al.   CLINICAL CANCER RESEARCH

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

(2014) Jordi Rodon et al.   INVESTIGATIONAL NEW DRUGS

The Phosphatidylinositol 3-Kinase (PI3K) Isoform Dependence of Tumor Formation Is Determined by the Genetic Mode of PI3K Pathway Activation Rather than by Tissue Type

(2014) T. Utermark et al.   JOURNAL OF VIROLOGY

PI3K and cancer: lessons, challenges and opportunities

(2014) David A. Fruman et al.   NATURE REVIEWS DRUG DISCOVERY

PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context

(2014) F. Schmit et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

(2013) Pascal Furet et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines

(2013) B. Weigelt et al.   CLINICAL CANCER RESEARCH

Enhanced PI3K p110  Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110 -Selective PI3K Inhibitor

(2013) S. W. Brady et al.   MOLECULAR CANCER THERAPEUTICS

Abstract 8: Genomic analyses of heterogeneous HER2 3+ invasive ductal carcinomas of the breast

(2012) Arnaud Gauthier et al.   CANCER RESEARCH

The p110  and p110  isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis

(2012) T. Utermark et al.   GENES & DEVELOPMENT

Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor

(2012) S. NYLANDER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110β as a Potential Anticancer Agent

(2012) Jing Ni et al.   Cancer Discovery

CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies

(2011) Jorge J Castillo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

(2011) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

(2011) Siyuan Zhang et al.   NATURE MEDICINE

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

(2010) Kimberly L. Blackwell et al.   JOURNAL OF CLINICAL ONCOLOGY

The emerging mechanisms of isoform-specific PI3K signalling

(2010) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Should individual PI3 kinase isoforms be targeted in cancer?

(2009) Shidong Jia et al.   CURRENT OPINION IN CELL BIOLOGY

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

(2008) P. J.A. Eichhorn et al.   CANCER RESEARCH

Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy

(2008) K. Twigger et al.   CLINICAL CANCER RESEARCH

ShcA signalling is essential for tumour progression in mouse models of human breast cancer

(2008) Josie Ursini-Siegel et al.   EMBO JOURNAL

Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration

(2008) Mariona Graupera et al.   NATURE

PTEN-deficient cancers depend on PIK3CB

(2008) S. Wee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA